A gentle drug plan kept one man's brain tumor steady for 3 months
Original title: Low-dose temozolomide combined with valproic acid in the treatment of an elderly patient with MGMT-methylated glioblastoma and multiple comorbidities: a case report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was one patient's story, not a trial in a group of people.
The short version
An 85-year-old man who was too frail for standard treatment stayed stable on two low-dose medicines.
What was studied. Doctors wrote up the case of one man, age 85, with a large brain tumor called glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. He was too sick for surgery and standard chemo and radiation, so he got a low daily dose of temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary, 50 mg/day, plus sodium valproate, 0.4 g three times daily.
What they found. The tumor was 6.4 cm x 6.0 cm and had some bleeding inside it. At the 3-month check, CT scans showed the tumor was stable and had not grown. He handled the medicines well, with no drop in blood counts and no liver trouble, and he could do a little more for himself than before.
What this means, and what it doesn't
What it could mean: For a patient who is too weak for standard care, a gentler drug plan may help hold a tumor steady for a while. It may also be easier on the body. A care team can say if something like this makes sense for one person.
What it doesn't mean: This is one patient's story, not a study. It does not show the plan works for other people. Three months is a short time to watch a tumor. This is not a cure, and it is not proven treatment.
Source: PubMed, July 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.